CERT | Ticker Profile - Titan Protect

CERT

Certara, Inc.

Healthcare · Health Information Services · NMS

$5.37

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$832M

Total market value of the company

Trailing P/E

N/A

Forward P/E

12.94

Based on estimated future earnings — lower means cheaper

Rev Growth

+0.9%

Year-over-year revenue change

Profit Margin

-3.6%

How much profit the company keeps from each dollar of revenue

ROE

-1.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$8.00

+49% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 11 analysts covering this stock

About Certara, Inc.

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

https://www.certara.com

Country: United States Employees: 1,515 Industry: Health Information Services

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.666

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0734

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.560

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-41.6%

Historical annualised return based on price data

Max Drawdown

-74.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.54

Significantly more volatile than the market

52W High

$13.88

61% below the year high

52W Low

$4.45

21% above the year low

Avg Volume

3,927,544

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

25.2%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.10

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

29.96

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.88

Healthy liquidity position

Quick Ratio

1.78

Like current ratio but excludes inventory — stricter test

Gross Margin

61.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

3.8%

Profit from core operations before interest and tax

Free Cash Flow

$117M

Positive — the business generates more cash than it spends

Revenue (TTM)

$420M

Total revenue over the last 12 months

Net Income

$-15,101,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$8.00

Target Low

$6.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go